SECOND AMENDMENT TO SUBLICENSE AGREEMENTSublicense Agreement • May 10th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2017 Company Industry JurisdictionTHIS SECOND AMENDMENT TO SUBLICENSE AGREEMENT (this “Amendment”) is made as of March 17, 2017 (the “Effective Date”) between Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“Checkpoint”), and TG Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“TGTX” and, together with Checkpoint, the “Parties”).
SECOND AMENDMENT TO LICENSE AGREEMENT (Amendment # 2)License Agreement • May 10th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2017 Company Industry JurisdictionTHIS SECOND AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is made as of March 31, 2017 (the “Effective Date”) between Jubilant Biosys Limited, a company organized under the laws of India, having its principal place of business at No. 96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore – 560022, India (“Licensor”), and Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“Checkpoint”).